Free Access
Med Sci (Paris)
Volume 22, Number 2, Février 2006
Page(s) 188 - 191
Section M/S revues
Published online 15 February 2006
  1. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129 : 92–6. [Google Scholar]
  2. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333 : 1600–7. [Google Scholar]
  3. Lyell A. Toxic epidermal necrolysis : an eruption resembling scalding of the skin. Br J Dermatol 1956; 68 : 355–61. [Google Scholar]
  4. Merot Y, Saurat JH. Clues to pathogenesis of toxic epidermal necrolysis. Int J Dermatol 1985; 24 : 165–8. [Google Scholar]
  5. Miyauchi H, Hosokawa H, Akaeda T, et al. T-cell subsets in drug-induced toxic epidermal necrolysis. Possible pathogenic mechanism induced by CD8-positive T cells. Arch Dermatol 1991; 127 : 851–5. [Google Scholar]
  6. Villada G, Roujeau JC, Clerici T, et al. Immunopathology of toxic epidermal necrolysis. Keratinocytes, HLA-DR expression, Langerhans cells, and mononuclear cells : an immunopathologic study of five cases. Arch Dermatol 1992; 128 : 50–3 [Google Scholar]
  7. Correia O, Delgado L, Ramos JP, et al. Cutaneous T-cell recruitment in toxic epidermal necrolysis, further evidence of CD8+ lymphocyte involvement. Arch Dermatol1993; 129 : 466–8. [Google Scholar]
  8. Paul C, Wolkenstein P, Adle H, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996; 134 : 710–4. [Google Scholar]
  9. Paquet P, Nikkels A, Arrese JE, et al. Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. Arch Dermatol 1994; 130 : 605–8. [Google Scholar]
  10. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282 : 490–3. [Google Scholar]
  11. Abe R, Shimizu T, Shibaki A, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas Ligand. Am J Pathol 2003; 162 : 1515–20. [Google Scholar]
  12. Paquet P, Pierard GE. Soluble fractions of tumor necrosis factor alpha, interleukin-6 and their receptors in toxic epidermal necrolysis : a comparison with second-degree burns. Int J Mol Med 1998; 1 : 459–62. [Google Scholar]
  13. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352 : 1586–9. [Google Scholar]
  14. Rhodes LE, Hashim IA, McLaughlin PJ, Friedmann PS. Blister fluid cytokines in cutaneous inflammatory bullous disorders. Acta Dermatol Venereol 1999; 79 : 288–90. [Google Scholar]
  15. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol2004; 140 : 890–2. [Google Scholar]
  16. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2003; 139 : 33–6. [Google Scholar]
  17. Brown KM, Silver GM, Halerz M, et al. Toxic epidermal necrolysis : does immunoglobulin make a difference ? J Burn Care Rehabil 2004; 25 : 81–8. [Google Scholar]
  18. Shortt R, Gomez M, Mittman N, et al. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004; 25 : 246–55. [Google Scholar]
  19. Berthou C, Michel L, Soulie A, et al. Acquisition of granzyme B and Fas ligand proteins by human keratinocytes contributes to epidermal cell defense. J Immunol 1997; 159 : 5293–300. [Google Scholar]
  20. Paquet P, Pierard GE. Keratinocyte injury in toxic epidermal necrolysis : simultaneous but distinct topographic expression of CD95R and calprotectin. Int J Mol Med 2002; 10 : 145–7. [Google Scholar]
  21. Gerber BO, Pichler WJ. Cellular mechanisms of T cell mediated drug hypersensitivity. Curr Opin Immunol 2004; 16 : 732–7. [Google Scholar]
  22. Le Cleach L, Delaire S, Boumsell L, et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol 2000; 119 : 225–30. [Google Scholar]
  23. Nassif A, Bensussan A, Dorothee G, et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 2002; 118 : 728–33. [Google Scholar]
  24. Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis : effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004; 114 : 1209–15. [Google Scholar]
  25. Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol 2004; 123 : 850–5. [Google Scholar]
  26. Shresta S, Pham CTN, Thomas DA, et al. How do cytotoxic lymphocytes kill their targets ? Curr Opin Immunol 1998; 10 : 581–7. [Google Scholar]
  27. Azukizawa H, Kosaka H, Sano S, et al. Induction of T-cell-mediated skin disease specific for antigen transgenically expressed in keratinocytes. Eur J Immunol 2003; 33 : 1879–88. [Google Scholar]
  28. Chung WH, Hung SI, Hong HS, et al. A marker for Stevens-Johnson syndrome. Nature 2004; 428 : 86. [Google Scholar]
  29. Hung SL, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102 : 4134–9. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.